Saturday 17 October 2026
Export MESO’s income statement to Excel — free account
Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
13.28
0.67
−4.80%
Follow MESO
| Dec '25 | Dec '24 | Dec '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 81.08 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (37.36) | |
P/B ratio |
— | — | — | 1.21 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 86.07 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (10.20) | |
EV/FCF |
— | — | — | (10.15) | |
Quick Ratio |
1.35 | 0.56 | 2.60 | 1.87 | |
Current Ratio |
1.58 | 0.96 | 2.71 | 1.95 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | (2.26) | |
Debt/Assets |
16.22% | 18.21% | 17.27% | 16.25% | |
Debt/Equity |
0.22 | 0.26 | 0.23 | 0.22 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.74 | |
Capex/Depreciation |
(0.11) | (0.05) | 0.00 | (0.04) | |
Interest Coverage |
— | — | — | (3.93) | |
Research and Development Expense of Revenue |
— | — | — | 347.84% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 295.22% | |
Intangible Assets out of Total Assets |
0.73 | 0.88 | 0.86 | 0.86 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 57.51% | |
Graham Net Nets |
— | — | — | (0.14) | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (14.32%) | |
Free Cash Flow Yield |
— | — | — | (10.45%) | |
Revenue per Share |
— | — | — | 0.02 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.21) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.92 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 6.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 6.45 | |
Free Cash Flow |
(30.83) | (20.76) | (0.20) | (16.31) | |
Working Capital |
74.41 | (3.07) | 53.79 | 39.68 | |
Capital Expenditures |
(0.48) | (0.11) | (0.20) | (0.04) | |
Net Current Asset Value |
(5.14) | (122.38) | (76.40) | (85.92) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
25.85 | 4.06 | 3.93 | 5.70 | |
Average Payables |
27.27 | 17.43 | 14.21 | 21.61 | |
Average Assets |
716.37 | 660.69 | 677.39 | 665.78 | |
Average Common Equity |
528.43 | 480.63 | 515.77 | 499.44 |
Columns are period end dates